Dispensação de medicamentos do componente especializado em polos no Estado do Rio de Janeiro Dispensing specialized component medicines in areas of the State of Rio de Janeiro

O Componente Especializado da Assistência Farmacêutica (CEAF) deve garantir dispensação de medicamentos de alto custo para o tratamento de doenças específicas. O fato desses medicamentos, previstos em listas oficiais, serem pleiteados por via judicial como estratégia de acesso à farmacoterapia sugere falhas na gestão da assistência. O presente estudo analisou a adesão aos Protocolos Clínicas e Diretrizes Terapêuticas (PCDT) no processo de dispensação de medicamentos do CEAF. Foi realizada uma pesquisa qualitativa em farmácias ambulatoriais de diferentes características no estado do Rio de Janeiro. Observou-se que a estrutura das unidades estudadas compromete a dispensação dos medicamentos do CEAF, havendo falta de recursos humanos capacitados. O fluxo de dispensação, fortemente dependente da interação entre prescritores e dispensadores, não é realizado como seria esperado. É possível que as fragilidades no desempenho das atividades tenham origem em falhas no planejamento e na organização de serviços. Os resultados indicam barreiras na adesão dos profissionais aos PCDT, prejudicando os usuários e podendo fomentar a busca da via judicial. Estima-se que as unidades investigadas sejam semelhantes a outras no país, e que as barreiras observadas se reproduzam, comprometendo a assistência.<br>The Specialized Pharmaceutical Services Component (CEAF) ensures the dispensing of high-cost medicines for the treatment of specific diseases. The fact that these medicines are mandatory though access is only through legal injunctions, suggests flaws in the management of pharmaceutical services. This paper analyzed adherence to Clinical Protocols and Therapeutic Guidelines (PCDT) in the dispensing of these CEAF medicines. Qualitative research was also conducted in facilities with different characteristics in the State of Rio de Janeiro. It was noted that the lack of adequate structure in the units studied, including trained personnel, compromises the dispensing CEAF medicines in all facilities. The CEAF dispensing procedure, heavily dependent on interaction between prescribers and dispensers, is not carried out as would be expected. It is possible that inadequate performance is also linked to flaws in the planning and organization of services. The results indicate barriers in adherence to PCDT by health professionals, prejudicing health system users and possibly leading them to access medicines by legal means. It is believed that characteristics of the investigated facilities are similar to others in Brazil, and the barriers identified may be the same, compromising healthcare

Atividades da farmácia hospitalar brasileira para com pacientes hospitalizados: uma revisão da literatura Pharmaceutical services for inpatients provided by hospital pharmacies in Brazil: a review of the literature

Este artigo discute a produção científica relacionada à farmácia hospitalar brasileira direcionada à internação, na tentativa de ampliar a visão sobre características e prioridades. Foram localizados dezessete artigos nas bases de dados Medline e Lilacs condizentes com os critérios de inclusão e exclusão definidos a priori. A maioria ateve-se aos componentes ensino/pesquisa, logística e farmacotécnica, a partir da observação de hospitais públicos localizados no Sudeste. Percebe-se a escassez de textos relacionados a atividades estruturais como gerenciamento e seleção. Estima-se que à formação acadêmica dos farmacêuticos atrele-se a percepção da manipulação como atividade preponderante nos serviços embora, atualmente, esta seja necessária apenas em um número restrito de hospitais. Soma-se a isto a baixa adequação das atividades realizadas a normas legais e padrões estabelecidos e a inexistência de revista brasileira dedicada ao tema e indexada pela BVS. Tendo em vista a maior freqüência de trabalhos oriundos do setor público, há, aparentemente, ou maior liberdade de atuação do farmacêutico neste setor ou menor produção científica, quantificada por publicações, no setor privado.<br>This paper discusses the literature on hospital pharmacy services for in-patients in Brazil, seeking a broader view of its characteristics and priorities. Seventeen papers were located in the Medline and Lilacs databases that complied with the pre-defined inclusion/exclusion criteria. Most of them were related to teaching and research, logistics and compounding, based on observations in public hospitals in Southeast Brazil. Few studies focused on core activities such as management and selection. The academic syllabus through which pharmacy students are trained may underlie the perception that compounding is the preponderant aspect of hospital pharmacy services, although this is required in only a few institutions. Added to this is poor compliance by pharmacy activities with established norms and standards and the lack of an indexed Brazilian publication in this field. As there were far more studies of the public sector than its private counterpart, it seems as though there is either greater freedom of action in the former or less scientific output in the latter, quantified by published studies

Terminologia de incidentes com medicamentos no contexto hospitalar Terminology for drug incidents in the hospital context

Incidentes com medicamentos geram problemas aos pacientes e custos adicionais ao sistema de saúde. A variedade de termos utilizada para comunicá-los propicia divergências nos resultados de pesquisas e confundem notificadores. Objetivou-se revisar os termos utilizados para descrever estes incidentes confrontando-os com as conceituações/definições oficiais disponíveis. Pesquisaram-se as bases PubMed, MEDLINE, IPA e LILACS para selecionar estudos publicados entre janeiro de 1990 e dezembro de 2005. Selecionaram-se 33 publicações. Verificou-se que a terminologia supranacional recomendada para descrever incidentes com medicamentos é insuficiente, mas que há consenso de uso das expressões em função do gênero do incidente. O termo Reação Adversa a Medicamento é mais utilizado quando não se verifica intencionalidade. A expressão Evento Adverso a Medicamento foi mais usada quando se descreviam incidentes durante a hospitalização; e Problema Relacionado a Medicamento foi mais utilizada em estudos que avaliaram atenção/cuidados farmacêuticos (uso/falta do medicamento). Ainda assim, a linha divisória entre essas três categorias não é clara e simples. Futuros estudos das relações entre as categorias e investigações multidisciplinares sobre erro humano podem subsidiar a proposição de novas conceituações.<br>In-hospital drug incidents cause problems for patients and additional costs for the health system. The variety of terms used to report them leads to disparities in research results and confuses the professionals that report them. This study aimed to review the terms used to describe drug incidents by collating them with the official concepts and definitions. PubMed, MEDLINE, IPA, and LILACS were searched to select studies published from January 1990 to December 2005. Thirty-three publications were selected. The supranational terminology recommended for describing drug incidents proved insufficient, but there was consensus that the expressions are used as a function of the type of incident. Adverse drug reaction is used when no intent is identified. Adverse drug event mainly describes incidents during hospitalization, and drug-related problem is used in studies on pharmaceutical care (use or lack of the drug). Still, the division between these categories is neither clear nor simple. Future studies on the relations between categories and multidisciplinary research on human error could support proposals for new concepts

Impact of pharmaceutical care on the quality of life of patients with Chagas disease and heart failure: randomized clinical trial

<p>Abstract</p> <p>Background</p> <p>Pharmaceutical care is the direct interaction between pharmacist and patient, in order to improve therapeutic compliance, promote adequate pharmacotherapeutic follow-up, and improve quality of life. Pharmaceutical care may be effective in reducing complications and in improving the quality of life of patients with chronic diseases, like Chagas heart disease, while bringing a positive impact on health system costs. The morbidity and mortality indexes for patients with Chagas heart disease are high, especially if this heart disease is complicated by heart failure. In this setting, we hypothesize that pharmaceutical care might be an important tool for the clinical management of these patients by improving their quality of life, as a better compliance to their treatment and the avoidance and prompt correction of drug-related problems will minimize their symptoms, improve their functional class, and decrease the number of hospital admissions. Therefore, the aim of this trial is to evaluate the contribution of pharmaceutical care to clinical treatment of patients with Chagas heart disease complicated by heart failure.</p> <p>Methods/design</p> <p>A prospective, single-center randomized clinical trial will be conducted in patients with Chagas heart disease complicated by heart failure. A total of 88 patients will be randomly assigned into two parallel groups: an intervention group will receive standard care and pharmaceutical care, and a control group will receive only standard care. Both groups will be subjected to a follow-up period of 12 months. The primary outcome of this trial is the evaluation of quality of life, measured by the 36-item short-form and the Minnesota Living with Heart Failure Questionnaire. Secondary outcomes include drug-related problems, exercise tolerance as measured by the standard six-minute-walk test, and compliance.</p> <p>Discussion</p> <p>Patients with Chagas heart disease complicated by heart failure under pharmaceutical care are expected to improve their quality of life, present with a lower incidence of drug-related problems, improve their functional capacity, and improve in their compliance to treatment.</p> <p>Trial registration</p> <p>ClinicalTrials.gov Identifier: NCT01566617</p